Abstract
PURPOSE: DNA ploidy has been shown to play a role in the response to cytotoxic therapy in a variety of malignancies, including breast cancer and melanoma. However, the importance of DNA ploidy in rectal cancer is unknown. The aim of the present study was to determine whether ploidy status might be associated with response to postoperative chemoradiation in TNM Stages II to III rectal cancer. METHODS: This retrospective study analyzed data from 229 patients with TNM Stages II to III rectal cancer who underwent resection between 1979 and 1984. The ploidy status and treatment modalities in relation to outcome were assessed. RESULTS: The recurrence-free ten-year survival rate was 52.2 percent for patients with diploidy and 50.5 percent for patients with nondiploidy (P=0.99). The ten-year survival rates for patients with diploidy and patients with nondiploidy were 55 and 19 percent (P=0.016) in the chemoradiation group, and 51 and 60 percent (P=0.15) in the nonchemoradiation group, respectively. In the chemoradiation group, DNA nondiploidy was associated with an increased recurrence rate (83.3vs. 50.0 percent;P=0.001). The interaction between DNA nondiploidy and chemoradiation remained important in predicting outcome in the Cox regression model. Factors independently correlated with a worse outcome included Stage IIIb (relative risk, 2.9; 95 percent confidence interval, 1.7–5;P=0.0001), perineural invasion (relative risk, 2.5; 95 percent confidence interval, 1.6–4,P=0.0001), distal tumor (relative risk, 1.7; 95 percent confidence interval, 1.1–2.7,P=0.014), and nondiploidy with chemoradiation (relative risk, 2.9; 95 percent confidence interval, 1.2–7.2,P=0.0213). CONCLUSIONS: These findings suggest that DNA nondiploidy is inversely correlated with long-term outcome among patients with high-risk rectal cancer receiving chemoradiation.
Similar content being viewed by others
References
Slanetz CA Jr, Herter FP, Grinnell RS. Anterior resectionvs. abdominoperineal resection for cancer of the rectum and rectosigmoid. Am J Surg 1972;123:110–7.
Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984;53:1354–62.
Dixon AR, Maxwell WA, Holmes JT. Carcinoma of the rectum: a 10-year experience. Br J Surg 1991;78:308–11.
Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465–72.
Krook JE, Moertel CG, Gunderson LL,et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709–15.
Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–67.
Fisher DE. Apoptosis in cancer therapy crossing the threshold. Cell 1994;73:539–42.
Anthoney DA, McIlwrath AM, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374–81.
Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45:450–6.
Offerhaus GJ, De Feyter EP, Cornelisse CJ,et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612–9.
Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;331:231–5.
Stal O, Skoog L, Rutqvist LE,et al. S-phase fraction and survival benefit from adjuvant chemotherapy of breast cancer. Br J Cancer 1994;70:1258–62.
Karlsson M, Jungnelius U, Aamdal S,et al. Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma. Int J Cancer 1996;65:1–5.
Hermanek P, Sobin LH, eds. UICC TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag, 1987:48–9.
Tang R, Ho YS, You YT,et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer 1995;76:1724–30.
Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192–6.
Delattre O, Olschwang S, Law DJ,et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353–6.
Meling GI, Lothe RA, Borresen AL,et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathologic variables. Br J Cancer 1993;67:93–8.
Carder PJ, Cripps KJ, Morris R,et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995;71:215–8.
Author information
Authors and Affiliations
Additional information
Supported by a grant (CMRP384) from Chang Gung Memorial Hospital.
About this article
Cite this article
Tang, R., Ho, YS., Chen, HH. et al. Different prognostic effect of postoperative chemoradiation therapy on diploid and nondiploid high-risk rectal cancers. Dis Colon Rectum 41, 1494–1499 (1998). https://doi.org/10.1007/BF02237295
Issue Date:
DOI: https://doi.org/10.1007/BF02237295